MR CLEAN Multicenter Randomized CLinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands C.B. Majoie, Y.B. Roos, A. van der.

Slides:



Advertisements
Similar presentations
Imaging Overview DIAS-4. Randomised, double-blind, parallel-group, placebo- controlled phase III study to evaluate the efficacy and safety of desmoteplase.
Advertisements

Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis on minimizing CT to recanalization times Michael D. Hill.
Some Difficult Stroke Cases: What Would You Do?
Beyond the Basics of Stroke Evaluation
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
Advanced Treatment Options for Stroke Patients Vickie Gordon PhD, ACNP-BC, CNRN.
ESCAPE Protocol Slides. What is the clinical question? Endovascular treatment for Small Core and Anterior circulation Proximal occlusion with Emphasis.
The Future of Stroke James D. Fleck, M.D. Medical Director IU Health Methodist Hospital Comprehensive Stroke Center.
Anticoagulation in Acute Ischemic Stroke. TPA: Tissue Plasminogen Activator 1995: NINDS study of TPA administration Design: randomized, double blind placebo-controlled.
Brain Single-Photon Emission CT With HMPAO and Safety of Thrombolytic Therapy in Acute Ischemic Stroke Proceedings of the Meeting of the SPECT Safe Thrombolysis.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
Neuroimaging of Ischemic Stroke With CT and MRI
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr.
Interventional Stroke Treatment 2015
European Stroke intervention Guidelines ESMINT/ESO/ESNR/EAN WLNC 2015
The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Brief Protocol Training NIH-NINDS U01 NS NETT CCC U01 NS NETT SDMC U01 NS
Maximizing IV Thrombolytic Therapy in Acute Ischemic Stroke Kamakshi Lakshminarayan, MD PhD Assistant Professor Neurology & Epidemiology University of.
UDATE ON REVASCAT: (Randomized Trial Of Revascularization With Solitaire FR® Device Versus Best Medical Therapy In The Treatment Of Acute Stroke Due To.
The Evolving Management of Pediatric Stroke Christopher A. Miller, MD July 21, 2012.
What’s on the horizon? Peter Sandercock ESC Lisbon 23rd May 2012.
Thrombolysis in acute ischaemic stroke – Updated Cochrane Thrombolysis metaanalysis JM Wardlaw, V Murray, PAG Sandercock University of Edinburgh and Karolinska.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
Evidence in the ED Byron Drumheller, MD Penn Emergency Medicine.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
The Stroke Oxygen Supplementation PILOT Study C. Roffe, K.Ali, A. Warusevitane, S. Sills, S. Pountain, P Jones, R Gray, P. Crome North Staffordshire Combined.
Intra - Arterial Thrombolysis for acute stroke
Terutroban versus aspirin in Patients with Cerebral Ischaemic Events (PREFORM): a Randomized, Double- blind Parallel-group Trial Daniel Wells Mercer University.
Treatment of Ischaemic Stroke The American Heart Association American Stroke Association Guidelines Stroke. 2007;38:
Mr X, 79 years old Admitted on 5/5/00 to WGH stroke unit Dense (0/5) right arm and leg paresis Aphasic CT scan excluded a bleed Given trial treatment (IST-3)
Simple CBF grading based on MR perfusion to anticipate long-term clinical outcome in severe stroke patients due to the carotid artery occlusion Mori T,
Recognition and Treatment of Large MCA Strokes Matthew S. Smith, MD, MS Director of Neurocritical Care Assistant Professor of Neurology Assistant Professor.
Can patients be too mild, too severe or too old for thrombolysis? Professor Peter Sandercock University of Edinburgh ESC Hamburg 27 th May 2011 Disclosures.
Long-term clinical outcome following emergency MR-based reperfusion therapy for acute middle cerebral artery occlusion Department of Stroke Treatment,
IST-3, SITS MOST ECASS-3 & DEFUSE Professor Peter Sandercock University of Edinburgh, UK ESC May 30 th 2007 Glasgow Competing interests:
Morphological and clinical results of invasive intra-arterial recanalization in the event of an acute stroke I Gubucz, Z Berentei, M Marosfői, C Óváry,
A multimodal step-up approach as rescue therapy of ischemic stroke L. Verganti, S. Vallone, C. Moratti, M. Malagoli, P. Carpeggiani Department of Neuroscience,
Long-Term Clinical Outcome After Emergency MR-based Reperfusion Therapy for Acute Basilar Artery Occlusion Department of Stroke Treatment, Shonan Kamakura.
Kim, Sun-Yong, M.D. Department of Radiology Ajou University Hospital, Suwon, Korea AGGRESIVE MECHANICAL CLOT DISRUPTION FOR ACUTE ISCHEMIC STROKE WITH.
ACUTE TREATMENT OF STROKE: RECENT ADVANCES AND PERFORMANCE AT CAMPBELLTOWN ALEX BUTTFIELD ED STAFF SPECIALIST.
Date of download: 5/31/2016 Copyright © The American College of Cardiology. All rights reserved. From: Mechanical Thrombectomy for Acute Ischemic Stroke:
ACUTE STROKE TREATMENT: An introduction Dec.2014
Abstract No: eEdE-103 Submission Number: Disclosure There is no disclosure.
Presentation: eP-26. There is no conflict of interest in this presentation.
University of Bologna, Italy Chair of Neuroradiology
Treating Acute Ischemic Stroke, Can We Open Up the Time Window?
ACUTE ISCHEMIC STROKE Olajide Williams, MD MS.
Hemicraniectomy in Older Patients with Extensive Middle-Cerebral-Artery Stroke DESTINY II TRIAL Katherine Steele 7 April 2014.
Multimodal Predictors of Massive Ischemic Stroke & Favourable Outcome.
Acute Stroke Management
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
Iwata T, Mori T, Tajiri H, Uesugi T, Nakazaki M
Direct catheter-based thrombectomy in acute ischemic stroke
Thrombectomy in Acute Stroke
Sameer A. Ansari, MD, PhD Associate Professor
Acute Carotid Occlusions
CAS in acute stroke C. Roth‡, P. Papanagiotou‡, A. M. Politi‡, K. W. Reith‡ Department of diagnostic.
Cardiovascular Research Technology Conference (CRT 17)
Baseline characteristics of the 3035 patients recruited in IST3
Mechanical thrombectomy
Olivier Bill1,3, Nuno M Inácio2, Dimitrios Lambrou1, Patrik Michel1.
PMA Analysis of the CREST Trial Approvability of the RX Acculink Carotid Stent System for Revascularization of Carotid Artery Stenosis in Standard Surgical.
Icahn School of Medicine Mount Sinai Hospital
Setareh Omran, MD Vascular Neurology Fellow
Update from education committee
The New Frontier In Stroke Care – Endovascular Intervention
Modified Rankin score 0-2
Extended Window Thrombectomy
Update from education committee
Presentation transcript:

MR CLEAN Multicenter Randomized CLinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands C.B. Majoie, Y.B. Roos, A. van der Lugt, R. van Oostenbrugge, W. van Zwam, D.W. Dippel, Depts of Radiology and Neurology, AMC Amsterdam, MUMC Maastricht and EMC Rotterdam, The Netherlands

MR CLEAN Trial Representative cases Rationale Purpose Design Trial organisation

36-y-o W, aphasia, R arm paresis

After stent retrieval: TICI 3 stent deployed

Good outcome 6d FU MRI

49 -Y-O M: L hemiparesis Pre IATPost IAT: TICI 3 Complete recanalization

Poor outcome CT 8hrs postprocedure

Rationale IAT increases likelihood of recanalization in patients with acute ischemic stroke, BUT..... Overall effect on functional outcome of IAT as compared to no IAT is unknown at present

Needed: a pragmatic clinical trial Intervention contrast should be closely matched to current evidence based practise (incl IVT hrs) No restrictions in type of treatment unless strictly necessary Clinical inclusion criteria (stroke severity, time since onset) as broad as possible

Purpose To assess the effect of IAT on functional outcome after acute ischemic stroke of ≤ 6 hour onset, in patients with a symptomatic proximal intracranial arterial occlusion

Hypothesis 10% absolute increase in the cumulative proportion of patients with mRS 0-2 in the intervention group, compared to control group

Design Pragmatic phase III multicenter clinical trial with blinded outcome assessment Intervention contrast is IAT* versus no IAT against a background of best medical management (incl IVT within 4.5 hrs) *IA thrombolysis and/or mechanical thrombectomy at discretion of neurointerventionalist, treatment guidelines provided by executive committee

Inclusion Criteria A clinical diagnosis of acute stroke –Deficit on NIHSS ≥ 2 (1,2) CT (or MRI) scan ruling out intracranial hemorrhage Proximal intracranial arterial occlusion on CTA –distal ICA; M1,M2; A1, A2 The possibility to start treatment ≤ 6 hours from onset Informed consent Age ≥ 18 Y 1.Derex Cerebrovasc Dis 2002; 2.Fisher Stroke 2006.

Patient Subgroups Patients –not responding to IV thrombolysis –who can be treated within 6 hours, but do not meet time window requirements for IVT –with contraindications for IV or IA thrombolytic treatment (thrombectomy only)

Design: outcomes Primary –mRS at 90 days Secondary –Imaging parameters TICI (DSA) Recanalization at 24 hours (CTA) Infarct size at 5-7 days (CT) Occurrence of major bleeding –Clinical parameters Mortality at 1 week and 90 days NIHSS score at hours and 1 week ALD (Academic Linear Disability) scale, EQ5D and Barthel index at 90 days

Subgroup analyses Treatment modality –Urokinase or rtPA dose –Mechanical thrombectomy Pretreatment with iv rt-PA Early vs late treatment Stroke severity (NIHSS)

Radiological Predictors of Improved Outcome CT/CTA Source: ASPECTS (Barber PA et al, Lancet 2000) CTA: Clot Burden Score (Puetz Int J Stroke 2008) CTA: Collateral score (Tan IYL, Ann Neurol 2007) CTP: Infarct size/Penumbra Index

Center Eligibility Experience: –in acute stroke trials –with endovascular interventions –specific: with IA thrombolysis and mechanical thrombecomy at least 5 cases in the preceding year (treatment and device-specific e.g. 5 cases treated with a retrievable stent)

Planning and logistics 500 patients 4 year inclusion period 13 actively participating centers: –10 patients per year per center

Conclusions MR CLEAN will provide insight into –Clinical and radiological predictors of good outcome –Clinical and radiological criteria that improve safety –Implementation strategies for best practises of endovascular treatment –Data for cost-effectiveness analyses

Probability of finding a prox art occlusion according to day 0 NIHSS (Derex L, Cerebrovasc Dis 2002)

Low initial NIHSS score and proximal occlusion Acute stroke patients with a low NIHSS score on admission should not be excluded from early imaging. Indeed, stroke in the hyperacute stage is a dynamic process with a potential for neurologic deterioration, even in patients with an initial mild stroke severity. Some of these patients with mild symptoms on admission may actually suffer from a large vessel occlusion and the clinical course of their stroke remains open, depending on many factors such as severity of the perfusion deficit, the adequacy of collateral circulation and the presence or absence of early recanalization Derex L Cerebrovasc Dis 2002;13:

Statistical Analysis Effect of treatment estimated by means of ordinal logistic regression (shift analysis), which considers whole range of mRS Sliding dichotomy: definition of good outcome customized to each patient’s baseline condition Murray GD et al. Design and analysis of phase III trials with ordered outcome scales: the concept of sliding dichotomy.J Neurotrauma 2005;22:511-17

Ordered outcome scales: concept of sliding dichotomy Murray et al (J Neurotrauma 2005) In stead of taking a single definition of “good outcome” for all patients (e.g.mRS ≤ 2), the definition is tailored to each patient’s baseline prognosis on entry of the trial. –For a patient with very severe injury survival alone might be regarded as good outcome –For a patient with a mild injury, only full recovery would be regarded as a good outcome Patients at the prognostic extremes have the potential to contribute to the estimation of treatment effect

Sliding Dichotomy Patients are grouped to a number of bands according to baseline prognosis Each band has a customized dichotomy of the outcome scale to differentiate between “good” and “bad” outcome The total number of good outcomes in the intervention group will be compared with the corresponding number of outcomes in the intervention group Murray et al (J Neurotrauma 2005)

Recanalization  Good outcome